
THRD
Healthcare · Biotechnology · $242.8M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2025
EPS trend, 90 days to now · -2.2% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 6, 2025 | Time not confirmed | -0.18 | 0.00 | +100.0% |
| Aug 14, 2025 | Time not confirmed | -0.23 | 0.00 | +100.0% |
| May 8, 2025 | Time not confirmed | -0.27 | -0.35 | -32.1% |
| Mar 27, 2025 | Time not confirmed | -0.35 | -0.30 | +15.5% |
| Nov 7, 2024 | Time not confirmed | -0.30 | -0.33 | -10.3% |
| Aug 8, 2024 | Time not confirmed | -0.25 | -0.26 | -4.0% |
| May 15, 2024 | Before the open | -0.31 | -0.20 | +35.5% |
| Mar 26, 2024 | Before the open | -0.31 | -0.17 | +45.2% |
| Nov 9, 2023 | Before the open | -0.27 | -0.19 | +29.6% |
| Aug 10, 2023 | Before the open | -0.30 | 0.19 | +163.3% |
| May 11, 2023 | After the close | -0.35 | -0.81 | -131.4% |
| Mar 29, 2023 | Before the open | -0.47 | -0.36 | +23.4% |
| Nov 9, 2022 | After the close | -0.41 |
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibitor for the…
| -0.69 |
| -68.3% |
| Sep 15, 2022 | After the close | — | -0.17 | — |